Results 111 to 120 of about 20,657 (229)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, Volume 20, Issue 3, Page 779-803, March 2026.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Terrace-like structure in the above-threshold ionization spectrum of an atom in an IR+XUV two-color laser field

, 2013
Based on the frequency-domain theory, we investigate the above-threshold ionization (ATI) process of an atom in a two-color laser field with infrared (IR) and extreme ultraviolet (XUV) frequencies, where the photon energy of the XUV laser is close to or ...
Chen, Jing, Fu, Panming, Hao, Xiao-Lei, Wang, Bingbing, Yan, Zong-Chao, Zhang, Kui   +5 more
core   +1 more source

Mechanistic role of GNE‐987 targeting BRD4‐HCP5 axis in pediatric T‐cell acute lymphoblastic leukemia

Journal of Cell Communication and Signaling, Volume 20, Issue 1, March 2026.
Abstract This study aims to explore the mechanism of action of the Bromodomain‐containing protein 4 (BRD4) inhibitor GNE‐987 in the treatment of pediatric T‐cell Acute Lymphoblastic Leukemia (T‐ALL), focusing on its effect in inhibiting T‐ALL cell proliferation by activating the HLA Complex P5 (HCP5) Super‐enhancer.
Xu Sang, Mengying Jiang, Yanchun Guan, Xin Chen, Zhen Zhang, Yumeng Wu, Wansheng Peng   +6 more
wiley   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

Tumor Organoids: Breakthroughs in Clinical Decision Making, Drug Development, and Translational Advances Beyond Conventional Models

Med Research, Volume 2, Issue 1, Page 26-40, March 2026.
ABSTRACT Tumor organoid models are revolutionizing cancer research by bridging the translational gap between conventional two‐dimensional cell cultures and animal models. This Editorial thoroughly explores the fundamental innovations of patient‐derived organoid technology.
Yimao Wu, Ruowei Sun, Gokhan Zengin, Shuai Ren, Meng‐Yao Li   +4 more
wiley   +1 more source

Quantitative central limit theorems for Mexican needlet coefficients on circular Poisson fields

, 2015
The aim of this paper is to establish rates of convergence to Gaussianity for wavelet coefficients on circular Poisson random fields. This result is established by using the Stein-Malliavin techniques introduced by Peccati and Zheng (2011) and the ...
Durastanti, Claudio
core   +1 more source

Correction: Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells

PLOS ONE, 2015
There is an error in Fig 2 that appears to have occurred during the preparation of files after the manuscript was accepted. In Fig 2B, the blot for Brd4 incorrectly appears as a duplicate of P-Brd4. The authors have provided a corrected version of Fig 2 here. Fig 2 Brd4 occupancy and expression in different cells.
Trent Fowler, Payel Ghatak, David H Price, Ronald Conaway, Joan Conaway, Cheng-Ming Chiang, James E Bradner, Ali Shilatifard, Ananda L Roy   +8 more
openaire   +3 more sources

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Molecular glue degraders (MGDs) constitute an emerging class of therapeutic agents poised to revolutionize the paradigm of targeted drug discovery. By reprogramming E3 ubiquitin ligases to degrade proteins of interest (POI) via a transient formation of a ternary complex mediated by protein–protein interactions, MGDs surpass the intrinsic limitations of
Jinfeng Wen, Jingtian Yu, Wuqiang Wen, Baishan Jiang   +3 more
wiley   +1 more source

A Facile Protocol for C(sp2)–C(sp3) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands

ChemMedChem, Volume 21, Issue 4, 25 February 2026.
A robust C(sp2)–C(sp3) decarboxylative coupling strategy enables access to new CRBN ligands and degraders with improved physicochemical properties. This synthetic approach is expanding the chemical space beyond C(sp2)–N linkages, fine‐tuning proteolysis‐targeting chimera activities and unlocking previously inaccessible degrader chemotypes.
Anita Maksutova, Thomas M. Geiger, Lorenzo Cianni, Dominika E. Pieńkowska, Jan Gerhartz, Lina Read, Aleša Bricelj, Alexander Herrmann, Maurice Leon Nelles, Yuen Lam Dora Ng, Marcus D. Hartmann, Jan Krönke, Izidor Sosič, Radosław P. Nowak, Michael Gütschow, Christian Steinebach   +15 more
wiley   +1 more source

Direct‐to‐Biology: Streamlining the Path From Chemistry to Biology in Drug Discovery

ChemMedChem, Volume 21, Issue 4, 25 February 2026.
Crude yet clever: Direct‐to‐biology workflows exploit nanoscale synthesis and plate‐based assays to accelerate hit discovery, save precious intermediates, and rethink early drug discovery. Direct‐to‐biology (D2B) has emerged as a transformative concept in early drug discovery, defined by the direct on‐target screening of crude reaction mixtures without
Ariane F. Hübner, Fabian Barthels
wiley   +1 more source